High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma

Annals of Oncology

Volumn 9, Issue SUPPL. 1, 1998, Pages

  Vose, J M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Autologous transplant; Non Hodgkin's lymphoma

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INTERLEUKIN 2; MELPHALAN; MESNA; METHYLPREDNISOLONE; MITOXANTRONE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0031953768     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_1.S1     Document Type: Review

References (26)

1. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-8.
2. Shipp MA, Yeap BY, Harrington DP et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: Analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990; 8: 84-93.
3. Meyer RM, Quirt IC, Skillings JR et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 1770-6.
4. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous hone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493-8.
5. Petersen FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-47.
6. Phillips GL, Fay JW, Herzig RH et al. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990; 75: 831-8.
7. Goldstone AH, Singer CRJ, Gribben JG et al. Experience of autologous bone marrow transplantation in the first 100 lymphomas. Bone Marrow Transplant 1988; 3: 33-6.
8. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-51.
9. Bosly A, Coiflier B, Gisselbrecht C et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10: 1615 23.
10. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
11. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination wiih high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117-22.
12. Rodriguez MA, Cabanillas FC, Velasquez W et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-41.
13. Sparano JA, Wiernik PH, Leaf A, Dutcher JP, Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071-9.
14. Girouard C, Dufresne J, Imre K el al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous hone marrow transplantation. Ann Oncol 1997; 8: 675-80.
15. Horning SJ, Negrin RS, Chao NJ et al. Fractionated total-body irradiation, etoposide. and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2552-8.
16. Gulati S, Yahalom J, Acaba L el al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide. and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936-41.
17. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527-34.
18. Higuchi CM, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77 (12): 2561-8.
19. Blaise D, Olive D, Stoppa AM et al. Hematologic and Immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092-7.
20. Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992: 517 26.
21. Kennedy MJ, Vogelsang GB, Jones RJ et al. Phase I trial of Interferon gamma to potentiate cyclosporinc-induced graftversus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249-57.
22. Grossbard ML,. Gribben JG, Freedman AS et al. Adjuvant Immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263-71.
23. McLaughlin P, Grillo-Lopez AJ, Czuczman M et al. IDEC-C2B8 (rituximab): Clinical activity in clinically chemoresistant low-grade or follicular lymphoma (LG F NHL) and in patients relapsing after anthracycline therapy or ABMT. Proc ASCO 1997; 16: 55a.
24. 131I-B1(Anti-CD20) antibody therapy with autologous stem-cell transplantation for relapsed B-cell lymphomas. Lancet 1995; 346: 336-40.
25. Vose JM, Rowlings PA, Lazarus HM et al. Multivariate analysis of autotransplant for patients with aggressive non-Hodgkin's lymphoma failing primary induction therapy. Proc ASH 1997.
26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.